HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
INSIDE INDUSTRY
Merck enters into license agreement with the Spanish National Cancer Research Centre

Merck Serono, the biopharmaceutical division of Merck, has signed a license agreement with the Spanish National Cancer Research Centre (CNIO) in Madrid in the area of cancer drug development. The global agreement will build upon CNIO research discoveries to encourage the development and commercialization of new compounds in the field of oncology.

The agreement encompasses the licensing of two series of new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.

"Part of Merck's commitment to oncology includes the focus on strategic agreements that allow us to foster a constant flow of innovations," said Andree Blaukat, Head of Translational Innovation Platform Oncology for Merck Serono. "We are convinced that working with like-minded organizations, like the CNIO, will further strengthen our efforts towards finding the next generation of breakthrough therapies."

"As a research organization, the CNIO is committed to fostering and promoting innovation. Among other initiatives, the CNIO's Experimental Therapeutics Program carries out early drug discovery projects. The CNIO is delighted to be working with Merck to hopefully translate this research into potential new treatment options for patients with cancer," said Maria Blasco, Director of the CNIO. "It is through collaborations with industry oncology leaders that we can bring CNIO discoveries, such as those made by the group led by Oscar Fernandez-Capetillo, to patients, and contribute new improved products to the battle against cancer."

ATR kinase has an important role in the response to DNA damage and in facilitating cell survival. Due to the fact that tumor cells accumulate more DNA damage than healthy cells, blocking ATR kinase activity with selective inhibitors appears to be a strategy worth investigating further for specific tumor types.

Source: PR Newswire

Click here for the complete issue.

NEWS CRUNCH  
news Medical technology experts to address the impact of innovation in shaping patient outcomes across Asia Pacific
news China biotech's 'coming out party' masks long road ahead
news SingHealth, Duke NUS and GSK to conduct large-scale big data study on asthma and COPD in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy